Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CCKAR | P32238 | 1/20 | 0.41 |
| ▸ | CCKBR | P32239 | 1/20 | 0.41 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.40 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL459673 | 0.97 | KMT2A (0.47) | KMT2AL3MBTL1CCKARCCKBRNPFFR1 | |
| SCHEMBL146760 | 0.97 | KMT2A (0.47) | KMT2AL3MBTL1CCKARCCKBRNPFFR1 | |
| SCHEMBL146759 | 0.97 | KMT2A (0.47) | KMT2AL3MBTL1CCKARCCKBRNPFFR1 | |
| SCHEMBL1721839 | 0.87 | KMT2A (0.46) | KMT2AL3MBTL1CCKARCCKBRNPFFR1 | |
| SCHEMBL149668 | 0.87 | KMT2A (0.46) | KMT2AL3MBTL1CCKARCCKBRNPFFR1 | |
| SCHEMBL149669 | 0.87 | KMT2A (0.46) | KMT2AL3MBTL1CCKARCCKBRNPFFR1 | |
| SCHEMBL149099 | 0.87 | KMT2A (0.46) | KMT2AL3MBTL1NPFFR1NPFFR2KCNA3 | |
| SCHEMBL1721675 | 0.87 | KMT2A (0.46) | KMT2AL3MBTL1NPFFR1NPFFR2KCNA3 | |
| SCHEMBL149100 | 0.87 | KMT2A (0.46) | KMT2AL3MBTL1NPFFR1NPFFR2KCNA3 | |
| SCHEMBL3932267 | 0.85 | L3MBTL1 (0.41) | KMT2AL3MBTL1BCHEMAOBDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | PROSIDION LIMITED (GB) | 2012-03-08 | — | — | US | disclosed |
| EP-2406251-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Prosidion Limited (GB) | 2012-01-18 | — | — | EP | disclosed |
| WO-2010103334-A1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | PROSIDION LIMITED (GB) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059014-A1 | Compounds for the Treatment of Metabolic Disorders | GPR119, FFAR2, GPBAR1 | KMT2A 3204/4885L3MBTL1 4277/4885CCKAR 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.